The E.U. Biotech Competitiveness Act: what it means for global pharma companies

Europe looks to shore up global competitiveness with the E.U. Biotech Act

Europe is at an inflection point in life sciences innovation. The E.U. Biotech Act is not simply another regulatory reform — it is a strategic response to a decade of declining global competitiveness.

As discussed in our recent TOPRA webinar, the real question for industry leaders is not whether the Act is ambitious, but whether it can meaningfully shift investment, accelerate development, and improve patient access outcomes in practice.

A structural competitiveness problem — now acknowledged

The starting point for the E.U. Biotech Act is clear-eyed: Europe has fallen behind.

Europe’s share of global commercial clinical trials has declined sharply over the past decade
Only a small proportion of global biotech venture capital flows into E.U.-based companies

At the same time, the geopolitical context has shifted. Biotech is now framed as a pillar of strategic autonomy, economic security, and industrial resilience—alongside AI and quantum technologies.

Clarivate webinar lens: This marks a fundamental repositioning. The E.U. is no longer treating biotech as a sectoral issue, but as core infrastructure for future economic leadership.

From friction to flow: targeting the real bottlenecks

The most immediate impact of the Act lies in addressing one of Europe’s persistent weaknesses: operational fragmentation in clinical development.

Key proposals include:

Reducing multinational trial approval timelines (from ~75 days to ~47 days)
Strengthening the role of a single “reporting member state” to reduce duplication
Enabling parallel processes for trial modifications
Introducing a reusable core dossier to streamline submissions

Today’s reality is a system where a single trial can effectively be re-evaluated multiple times across member states—creating delays, inconsistency, and cost inefficiency.

The Act aims to replace this with a model built on mutual trust and coordinated review.

Clarivate webinar lens: If fully operationalised, this could materially narrow the execution gap between Europe and more agile markets like the U.S. and Mainland China. However, historical precedent suggests that regulatory intent and on-the-ground experience can diverge significantly.

Innovation mechanisms: promise without full definition

Beyond efficiency, the Act introduces a new toolkit designed to accelerate next-generation innovation:

Regulatory sandboxes: controlled testing environments for emerging technologies such as AI and advanced therapies
Expanded AI integration across development and regulatory processes
Public-private funding models to crowd in investment
Support infrastructure for biotech SMEs and scale-ups

These mechanisms reflect a shift toward more adaptive, innovation-friendly regulation. However, their practical application remains nascent.

Clarivate webinar lens: The opportunity is real — but early. Companies that engage proactively in pilots and shape implementation will have an advantage over those waiting for regulatory clarity.

Incentives: necessary, but not yet sufficient

A central question for executives is whether the E.U. is creating a competitive enough environment to attract investment.

The headline incentive — a 12-month extension of supplementary protection certificates (SPCs) — is directionally positive but conditional:

Multinational E.U. trials are required
An E.U.-based manufacturing presence is required
A novel mechanism of action criteria is applied

While meaningful, these incentives may still lag behind those offered in the U.S. or emerging Asian hubs.

Clarivate webinar lens: The E.U. is signalling intent — but the strength of the investment case will depend on final implementation and the balance between incentives and operational complexity.

The strategic shift: Europe as a data and evidence engine

Perhaps the most underappreciated shift is the Act’s focus on anchoring evidence generation within Europe.

By:

Driving more clinical trials into E.U. populations
Aligning development with E.U. HTA and regulatory requirements
Supporting comparative and real-world evidence generation

…the Act aims to reposition Europe as a hub not just for innovation, but for decision-grade evidence.

This is particularly critical as Joint Clinical Assessments (JCAs) and broader pharma reforms increase scrutiny on value demonstration.

Clarivate insight: Competitive advantage will increasingly depend on getting the evidence strategy right early — integrating regulatory, HTA, and payer requirements from the outset.

The execution gap: where the outcome will be decided

The E.U. Biotech Act is ambitious in scope — seeking to align regulation, innovation, and access into a coherent ecosystem.

However, three risks remain:

Implementation complexity as multiple reforms (pharma package, JCAs, device regulation) roll out simultaneously
Potential dilution of key provisions during the legislative process
Operational realities — including resourcing, IT infrastructure, and cultural shifts across member states

Success ultimately hinges on whether the system can truly shift toward:

Faster decision-making
Greater mutual reliance
More predictable pathways for innovators

What executives should do now

Engage early in shaping implementation
Regulatory sandboxes, pilots (e.g. fast-track trial initiatives), and stakeholder consultations will define how the Act works in practice.
Recalibrate E.U. development strategy
Design trials and evidence generation plans with European access requirements embedded from day one.
Monitor incentives and legislative evolution closely
Final details on SPCs, funding instruments, and operational rules will materially impact investment decisions.

Bottom line

The E.U. Biotech Act represents a credible attempt to reposition Europe in a rapidly shifting global biotech landscape.

But legislation alone will not close the competitiveness gap.

Execution will.

For industry leaders, the imperative is clear: move from passive observation to active participation—because the companies that help shape the system will be best positioned to benefit from it.

View the webinar here: Is the EU Biotech Act Europe’s innovation turning point? | Clarivate

Explore how global regulatory intelligence across the product lifecycle supports informed regulatory decision making.